NewEdge Wealth LLC Has $541,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

NewEdge Wealth LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 17.1% in the 4th quarter, HoldingsChannel reports. The fund owned 7,098 shares of the medical research company’s stock after purchasing an additional 1,039 shares during the quarter. NewEdge Wealth LLC’s holdings in Edwards Lifesciences were worth $541,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. Nordea Investment Management AB lifted its holdings in Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after purchasing an additional 1,488,791 shares during the last quarter. Arlington Trust Co LLC grew its position in shares of Edwards Lifesciences by 5,092.4% during the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after purchasing an additional 12,069 shares in the last quarter. Versor Investments LP raised its position in shares of Edwards Lifesciences by 83.3% in the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after buying an additional 2,043 shares in the last quarter. Gateway Investment Advisers LLC boosted its stake in shares of Edwards Lifesciences by 12.2% in the fourth quarter. Gateway Investment Advisers LLC now owns 253,337 shares of the medical research company’s stock valued at $19,317,000 after buying an additional 27,519 shares during the period. Finally, US Bancorp DE grew its position in Edwards Lifesciences by 0.6% during the third quarter. US Bancorp DE now owns 850,257 shares of the medical research company’s stock worth $58,906,000 after buying an additional 5,409 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares in the company, valued at $16,049,739.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock worth $17,166,254 in the last ninety days. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Trading Up 1.0 %

Shares of EW stock opened at $90.06 on Wednesday. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The stock’s fifty day simple moving average is $90.11 and its 200 day simple moving average is $78.07. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $54.21 billion, a P/E ratio of 39.16, a P/E/G ratio of 4.47 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the firm posted $0.64 earnings per share. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on EW shares. Royal Bank of Canada lifted their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday. Stifel Nicolaus boosted their price target on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a research note on Friday, February 2nd. Oppenheimer boosted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Finally, Mizuho increased their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.